48.37
前日終値:
$47.80
開ける:
$48.31
24時間の取引高:
1.93M
Relative Volume:
0.74
時価総額:
$121.02B
収益:
$48.62B
当期純損益:
$6.80B
株価収益率:
17.25
EPS:
2.8038
ネットキャッシュフロー:
$7.62B
1週間 パフォーマンス:
+1.57%
1か月 パフォーマンス:
-6.94%
6か月 パフォーマンス:
-0.12%
1年 パフォーマンス:
+0.08%
Sanofi Adr Stock (SNY) Company Profile
SNY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
48.37 | 121.02B | 48.62B | 6.80B | 7.62B | 2.8038 |
![]()
LLY
Lilly Eli Co
|
795.12 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.01 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVO
Novo Nordisk Adr
|
67.70 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
ABBV
Abbvie Inc
|
186.79 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
120.32 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
2025-03-21 | 開始されました | Goldman | Neutral |
2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
2024-07-26 | 繰り返されました | Argus | Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-10-30 | ダウングレード | Stifel | Buy → Hold |
2023-09-06 | アップグレード | Berenberg | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
2022-12-13 | 再開されました | Morgan Stanley | Overweight |
2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
2022-08-09 | ダウングレード | UBS | Buy → Neutral |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 開始されました | Deutsche Bank | Sell |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
2020-03-11 | アップグレード | Goldman | Neutral → Buy |
2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 開始されました | Bernstein | Outperform |
2019-08-14 | アップグレード | UBS | Neutral → Buy |
2018-12-11 | アップグレード | Jefferies | Hold → Buy |
2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
2018-03-23 | アップグレード | Liberum | Hold → Buy |
2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - FinancialContent
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
Can Navitas Semiconductor Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Procore Technologies Inc (PCOR) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Navigating TREE Stock: LendingTree Inc Journey - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
Analyzing the Impact of Earnings Reports on Sunstone Hotel Investors Inc Inc. (SHO) Price Performance - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
TTWO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
CTRE’s Market Whiplash: 5.78% YTD Rise, 0.22% Rise in 30 Days - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Canadian National Railway Co: Navigating Market Fluctuations with a 62.62B Market Cap - investchronicle.com
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):